Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of VCEL is 52 and suggests 55% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell